CN1235968A - 取代的三环化合物 - Google Patents

取代的三环化合物 Download PDF

Info

Publication number
CN1235968A
CN1235968A CN99108097A CN99108097A CN1235968A CN 1235968 A CN1235968 A CN 1235968A CN 99108097 A CN99108097 A CN 99108097A CN 99108097 A CN99108097 A CN 99108097A CN 1235968 A CN1235968 A CN 1235968A
Authority
CN
China
Prior art keywords
alkyl
phenyl
group
nitrogen
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99108097A
Other languages
English (en)
Chinese (zh)
Inventor
N·J·巴奇
J·A·巴斯蒂安
D·W·贝特
M·D·金尼克
M·J·马蒂内利
E·D·米赫利奇
小J·M·莫林
D·J·萨尔
J·S·肖耶
E·C·R·史密斯
T·苏尔雷兹
王秋萍
T·M·维尔逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1235968A publication Critical patent/CN1235968A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/70[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN99108097A 1998-04-17 1999-04-16 取代的三环化合物 Pending CN1235968A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6216598A 1998-04-17 1998-04-17
US09/062165 1998-04-17

Publications (1)

Publication Number Publication Date
CN1235968A true CN1235968A (zh) 1999-11-24

Family

ID=22040624

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99108097A Pending CN1235968A (zh) 1998-04-17 1999-04-16 取代的三环化合物

Country Status (27)

Country Link
EP (2) EP0950661B1 (https=)
JP (1) JP4435325B2 (https=)
KR (1) KR19990083234A (https=)
CN (1) CN1235968A (https=)
AR (1) AR018185A1 (https=)
AT (2) ATE254128T1 (https=)
AU (1) AU757454B2 (https=)
BR (1) BR9901275A (https=)
CA (1) CA2269256A1 (https=)
CO (1) CO5080728A1 (https=)
CZ (1) CZ137199A3 (https=)
DE (2) DE69912670T2 (https=)
EA (1) EA003129B1 (https=)
ES (2) ES2213668T3 (https=)
HU (1) HUP9901219A1 (https=)
ID (1) ID23219A (https=)
IL (1) IL129484A0 (https=)
NO (1) NO991823L (https=)
NZ (1) NZ335252A (https=)
PE (1) PE20000472A1 (https=)
PL (1) PL332564A1 (https=)
SG (1) SG106035A1 (https=)
SV (1) SV1999000052A (https=)
TR (1) TR199900842A2 (https=)
TW (1) TW555760B (https=)
YU (1) YU19099A (https=)
ZA (1) ZA992773B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301586A1 (en) * 1997-08-28 1999-03-04 William Louis Macias Method for treatment of non-rheumatoid arthritis
WO2001074817A1 (en) * 2000-03-30 2001-10-11 Yamanouchi Pharmaceutical Co., Ltd. Hydrazide derivatives
EP1303262A2 (en) * 2000-07-14 2003-04-23 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
WO2002050029A2 (en) * 2000-12-18 2002-06-27 Eli Lilly And Company Tetracyclic derivatives as spla2 inhibitors
CA2441077A1 (en) 2001-03-28 2002-10-10 Eli Lilly And Company Substituted carbazoles as inhibitors of spla2
US7160909B2 (en) 2001-08-09 2007-01-09 Eli Lilly And Company Cyclopenta[b]indole derivatives as sPLA2 inhibitors
US7109231B2 (en) 2001-08-09 2006-09-19 Eli Lilly And Company Cyclohept[b]indole derivatives
US6992100B2 (en) 2001-12-06 2006-01-31 Eli Lilly And Company sPLA2 inhibitors
WO2006050007A2 (en) 2004-11-01 2006-05-11 Wyeth Substituted indolizines and derivatives as cns agents
US8716308B2 (en) 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
DK2697223T3 (en) * 2011-04-14 2016-09-05 Actelion Pharmaceuticals Ltd 7- (heteroaryl-amino) -6,7,8,9-tetrahydro-pyrido [1,2-a] indole-acetic acid derivatives and their use as prostaglandin D2 receptor
SI2825541T1 (sl) 2012-03-16 2016-10-28 Vitae Pharmaceuticals, Inc. Modulatorji jetrnega receptorja X
ES2607113T3 (es) 2012-03-16 2017-03-29 Vitae Pharmaceuticals, Inc. Moduladores de los receptores X del hígado

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
BR9508298A (pt) * 1994-07-21 1998-11-03 Shionogi & Co Inibidores de indolizina de spla2
EP0779271B1 (en) * 1995-12-13 2001-08-01 Eli Lilly And Company Naphthyl acetamides as sPLA2 inhibitors
CA2269203A1 (en) * 1996-10-30 1998-05-07 Nicholas James Bach Substituted tricyclics
EP1007056A1 (en) * 1997-09-26 2000-06-14 Eli Lilly And Company Method for the treatment of cystic fibrosis
WO1999025340A1 (en) * 1997-11-14 1999-05-27 Eli Lilly And Company Treatment for alzheimer's disease

Also Published As

Publication number Publication date
EP1156050A2 (en) 2001-11-21
BR9901275A (pt) 2000-05-02
AR018185A1 (es) 2001-10-31
SG106035A1 (en) 2004-09-30
DE69914951T2 (de) 2004-12-23
TR199900842A2 (xx) 2000-09-21
ZA992773B (en) 2002-07-16
EP1156050A3 (en) 2001-11-28
SV1999000052A (es) 2000-03-14
KR19990083234A (ko) 1999-11-25
ATE259818T1 (de) 2004-03-15
AU2381899A (en) 1999-10-28
NZ335252A (en) 2000-11-24
CO5080728A1 (es) 2001-09-25
ID23219A (id) 2000-03-30
CZ137199A3 (cs) 1999-11-17
YU19099A (sh) 2001-09-28
DE69914951D1 (de) 2004-03-25
DE69912670D1 (de) 2003-12-18
ES2210979T3 (es) 2004-07-01
EA199900304A3 (ru) 2000-04-24
EA199900304A2 (ru) 1999-10-28
EP1156050B1 (en) 2004-02-18
TW555760B (en) 2003-10-01
PL332564A1 (en) 1999-10-25
PE20000472A1 (es) 2000-06-02
ATE254128T1 (de) 2003-11-15
IL129484A0 (en) 2000-02-29
ES2213668T3 (es) 2004-09-01
NO991823L (no) 1999-10-18
AU757454B2 (en) 2003-02-20
HU9901219D0 (en) 1999-06-28
DE69912670T2 (de) 2004-08-12
JPH11322745A (ja) 1999-11-24
CA2269256A1 (en) 1999-10-17
HUP9901219A1 (hu) 2000-08-28
JP4435325B2 (ja) 2010-03-17
EA003129B1 (ru) 2003-02-27
NO991823D0 (no) 1999-04-16
EP0950661B1 (en) 2003-11-12
EP0950661A1 (en) 1999-10-20

Similar Documents

Publication Publication Date Title
CN1036920C (zh) 含杂环碳酸衍生物
CN1149193C (zh) 取代的三环化合物
CN1050605C (zh) 环烷并吲哚和环烷并氮杂吲哚衍生物,其制备方法和含有它们的药物组合物
CN1028104C (zh) 制备喹诺酮衍生物的方法
CN1035508A (zh) 新的取代的喹啉衍生物的制备方法
CN1235968A (zh) 取代的三环化合物
CN1215059C (zh) 新的杂环化合物及其盐和它们的医药用途
CN1233176A (zh) 取代的三环化合物
CN1085556A (zh) 抗偏头痛的吲哚-3-基烷基哌嗪的4-嘧啶基和吡啶基衍生物
CN1210521A (zh) 异喹啉衍生物及医药
CN1549814A (zh) 作为1型纤溶酶原激活物抑制剂(pai-1)的抑制剂的取代萘基吲哚衍生物
CN1320037A (zh) 抗病毒的吲哚氧代乙酰基哌嗪衍生物
CN1302300A (zh) 吡咯并[1,2-b]哒嗪sPLA2抑制剂
CN1092766A (zh) 药物
CN1545513A (zh) 新颖的2h-哒嗪-3-酮衍生物、含有它们的药物组合物和活性成分的制备方法
CN1096784A (zh) 含取代4(5)-氨基-1,8-二氨杂萘的治疗剂
CN1083059A (zh) 3-哌啶甲基羧酸酯取代的吲哚
CN1107158A (zh) 多取代的2-氨基-噻唑衍生物
CN1265660A (zh) 2-(4-芳基或杂芳基-哌嗪-1-基甲基)-1h-吲哚衍生物
CN1993344A (zh) 可用作香草素拮抗剂的色酮衍生物
CN1117731A (zh) 具有抑制精神病活性的芳香杂环化合物
CN1234801A (zh) 5h-吡咯并[2,1-c][1,4]-苯并二氮杂䓬的3-甲酰胺衍生物
CN1553814A (zh) 用于治疗动脉硬化的药物组合物
CN101039943A (zh) 作为抗癌剂的新型吖吲哚噻唑啉酮
CN1017901B (zh) 抗精神病药稠环吡啶基哌嗪衍生物的制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication